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In the Statin Era, How Important
Are Intense Lifestyle Changes?*
William W. Parmley, MD, MACC
San Francisco, California
The patient sitting across from me in my office seems to
have lipids controlled with a reasonable diet and a daily
statin. He asks, “Doctor, can I have an occasional steak, and
an occasional hot fudge sundae?” As a believer in the
importance of quality of life, I am likely to concur with such
a request. In my mind I am probably rationalizing that the
statin will easily cover such indiscretions because of its
powerful effects in both primary and secondary prevention.
In this issue of the Journal, Sdringola et al. (1) suggest
that my attitude may be too cavalier. They make a case for
intense lifestyle changes bringing added benefit to patients
on top of statin therapy. A total of 409 consecutive
unselected patients with coronary artery disease (CAD) had
baseline positron emission tomography imaging, repeat
imaging at about two and half years, with additional
follow-up for five more years. The level of treatment during
this time was classified as: poor  no dietary control or
lipid-active drugs; moderate  American Heart Association
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diet plus lipid-lowering drugs or on a strict low fat diet
(10% of calories); and maximal  diet (10% of calories
as fat), regular exercise, weight loss, monthly follow-up, and
lipid-active drugs dosed to target cholesterol goals (LDL
[low-density lipoprotein] 90 mg/dl). Over the five-year
period, coronary events occurred in 6.6%, 20.3%, and 30.6%
of patients in the maximal, moderate, and poor treatment
groups, respectively. This data is first of all an affirmation
that lipid-lowering is beneficial in reducing coronary events.
Similarly, lipid-lowering improved myocardial perfusion
judged by PET scan (2). This effect presumably occurred by
improved endothelial function and/or plaque regression.
The new question of importance, however, is the potential
independent benefit from intense lifestyle changes (3).
One of the difficulties in answering the question posed by
Sdringola et al. (1) is that this was not a randomized trial. In
their introduction, the investigators make a compelling case
as to why randomization would be difficult if not impossible.
Nevertheless, this remains a major problem with the present
study. We have recent examples of how observational
studies have been strongly contradicted by subsequent
prospective, placebo-controlled, randomized trials. Obser-
vational studies of vitamin E intake strongly suggested
benefit from taking this antioxidant vitamin (4–6). The
rationale seemed intuitive that an antioxidant vitamin would
counter the adverse effects of oxidized LDL cholesterol.
However, the large placebo-controlled Heart Outcomes
Prevention Evaluation (HOPE) (7) and Heart Protection
Studies (8) failed to show any benefit from vitamin E.
In a similar way, observational studies of hormone re-
placement therapy (HRT) have suggested considerable
benefit in protecting postmenopausal women from cardio-
vascular events (9–11). Again, the rationale seems indisput-
able. Prior to menopause the female hormones seem to be
protective, by a number of mechanisms, thus explaining the
higher risk in men. After menopause there is a catch-up
phenomenon, whereby women have more events than men,
a sequence so easily explained by the loss of their protective
hormones. Thus, it was quite a surprise when the Heart and
Estrogen/progestin Replacement Study (HERS) (12) and
the Women’s Health Initiative (13) failed to show protec-
tion with HRT in women, and in fact were suggestive of
harm.
These two recent examples remind us of a major pitfall of
nonrandomized observational studies: you simply cannot
control for, or know, all of the variables that affect outcome.
In the two observational examples cited above, the patients
who benefited from vitamin E (4–6) or HRT (9–11) were
probably doing other “healthy things,” which improved the
outcome. In the present trial (1), intense lifestyle changes
may have been the other “healthy things” that improved the
outcome, but we cannot prove it by this study design.
Missing data in this study are the baseline lipids, al-
though there is a similar distribution of patients in the three
groups, those who have “hypercholesterolemia,” hypertri-
glyceridemia,” and “low high-density lipoprotein (HDL).”
When examining the follow-up lipid data, the simplest
explanation for the difference in clinical events is the
difference in lipids (Table 2 in Sdringola et al. [1]). For the
maximal, moderate, and poor treatment groups the total
cholesterol levels were 140, 184, and 226 mg%, and the
LDL cholesterol levels were 74, 111, and 143 mg%,
respectively. This leaves the unanswered question: If lipid
levels were the same in all three groups (by adjusting
statins), would there have been a similar clinical event rate?
In other words, is lowering lipids by intense lifestyle changes
to the same extent as statins equally protective?
Another question related to the study by Sdringola et al.
(1) is whether all the benefit is related to the level of lipids
achieved. In the Scandinavian Simvastatin Survival Study
(4S) study with simvastatin in patients with known vascular
disease and very high levels of LDL cholesterol, there was a
similar percentage reduction in clinical events in patients
from all quartiles of initial LDL cholesterol (14). Con-
versely, in the Cholesterol And Recurrent Events (CARE)
trial (15) postmyocardial infarction, it appeared that prava-
chol was beneficial only in patients with an initial baseline
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LDL cholesterol 125 mg%. However, in the much larger
Heart Protection Study (16) there was an equal percent
benefit from simvastatin in each tertile of LDL cholesterol,
including patients who started below 100 mg%. This
suggests that LDL goal levels may be overemphasized since
the use of statins may be the key. This may reflect other
beneficial effects of statins, such as anti-inflammatory and
antithrombotic effects, among other benefits. Relative to the
present study, the use of statins in the maximal, moderate,
and poor treatment groups was 89%, 64%, and 15%,
respectively. Thus, the markedly differing use of statins may
have played a role in the results cited by the investigators
(1). In contrast, intense lifestyle changes such as exercise,
diet, and weight loss may also have other independent
benefits besides lowering cholesterol.
Conclusions. In summary, the study by Sdringola et al. (1)
is very important in emphasizing the benefit of life-
style changes and risk factor reduction along with lipid-
lowering therapy. It seems reasonable to employ a broad-
based approach to both primary and secondary prevention,
rather than to depend only on a pill. Because the study by
Sdringola et al. (1) was not randomized, it cannot unequiv-
ocally prove the added benefit of lifestyle changes. Never-
theless, I agree with the investigators in their important
findings that a combination of lifestyle changes and lipid-
lowering therapy caused an optimal reduction in clinical
events.
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